Authors
Latest:
Dr. Bustoros on Next-Generation Sequencing in Multiple MyelomaMark W. Bustoros, MD, Dana-Farber Cancer Institute, discusses the role of next-generation sequencing for patients with multiple myeloma.
Latest:
Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600-Mutant DiseaseMark W. Kieran, MD, PhD, director, pediatric medical neuro-oncology, institute physician associate professor of pediatrics, Harvard Medical School, discusses the first study of dabrafenib in pediatric patients with BRAF V600–mutant disease.
Latest:
Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast CancerCtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.
Latest:
Dr. Albertsmeier on Radiotherapy Improving the Local Control of SarcomaMarkus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses radiotherapy improving the local control for patients with sarcoma.
Latest:
Dr. Renschler Discusses Updated Results of the MPACT StudyMarkus Renschler, MD, vice president, global head, Hematology Oncology Medical Affairs at Celgene, discusses updated results of the MPACT study, which examined nab-paclitaxel plus gemcitabine vs gemcitabine for patients with metastatic pancreatic cancer.
Latest:
Urology Practices Form Collaborative Partnerships With Specialty Pharmacy ProvidersNovel formulations of specialty drugs have shifted the treatment of patients taking oncologic and biologic agents from infusion centers to the doctor's office.
Latest:
Dr Posner on the Mechanism of Action of Danivatirsen in HNSCCMarshall Posner, MD, discusses the mechanism of action of danvatirsen in recurrent and/or metastatic head and neck squamous cell carcinoma.
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment RecommendationsResearchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Latest:
Dr. Martee Hensley on Trabectedin as a Treatment for Uterine LeiomyosarcomaMartee Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the introduction of trabectedin into the armamentarium for uterine leiomyosarcoma. Hensley says the FDA approval for the treatment requires patients to have had a prior anthracycline therapy, and the treatment will likely fall into the third- or fourth-line of treatment for the malignancy. She adds that trabectedin may fall into the fourth-line due to treatments such as pazopanib currently occupying the third-line.
Latest:
Dr. Hensley on dMRR and MSI-H Testing in Endometrial CancerMartee L. Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses DNA mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) testing for patients with endometrial cancer.
Latest:
Dr. Arellano on Managing Older Patients With AMLMartha L. Arellano, MD, discusses the management of older patients with acute myeloid leukemia.
Latest:
Martin Barrett on Intravenous Versus Subcutaneous RituximabMartin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic CancerAn integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Latest:
An Overview of the Molecular Characterization of Lung LCNECPanelists discuss how the characterization and classification of lung large cell neuroendocrine carcinoma (LCNEC) has evolved over the past decade, highlighting the clinical heterogeneity of these tumors and how it is navigated in clinical practice.
Latest:
Dr. Dreyling on Key Safety Data from the TRIANGLE Trial in MCLMartin Dreyling, MD, discusses the key safety data from the phase 3 TRIANGLE trial in younger patients with mantle cell lymphoma.
Latest:
Dr. Gutierrez on the Investigation of MK-0482 in Advanced Solid TumorsMartin E. Gutierrez, MD, discusses the investigation of MK-0482 in advanced solid tumors.
Latest:
Dr. Forster on Next Steps With Lurbinectedin in SCLCMartin Forster, MD, a medical oncologist, University College London Hospitals, discusses the next steps with the investigational agent lurbinectedin in combination with doxorubicin as a second-line therapy for patients with small cell lung cancer (SCLC).
Latest:
Dr Voss on the Evaluation of Nivolumab/Ipilimumab in Intermediate/Poor-Risk RCCMartin H. Voss, MD, discusses the evaluation of nivolumab plus ipilimumab in IMDC-classified intermediate/poor-risk renal cell carcinoma.
Latest:
Dr Voss on the Clinical Significance of the KEYNOTE-564 Study in ccRCCMartin H. Voss, MD, discusses the clinical significance of the phase 3 KEYNOTE-564 trial in clear cell renal cell carcinoma.
Latest:
Dr. Hutchings on Subgroup Analysis of ECHELON-1 in Hodgkin LymphomaMartin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.
Latest:
Dr. van den Bent on Temozolomide and Depatux-M in GlioblastomaMartin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the combination of temozolomide (Temodal) and depatuxizumab mafodotin (depatux-m) in the treatment of patients with glioblastoma.
Latest:
Dr. Reck on Updated Results of the CheckMate 9LA Trial in Advanced NSCLCMartin Reck, MD, PhD, discusses updated results of the phase 3 CheckMate 9LA study in advanced non–small cell lung cancer.
Latest:
Dr. Tallman on FDA Approval of Midostaurin in AMLMartin S. Tallman, MD, chief, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of midostaurin (PKC412) for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).
